Results 211 to 220 of about 637,031 (303)

Lower Extremity Sprains and Knee/Ankle Injury Predominate Among Pediatric Dancers

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To determine the most common body regions, diagnoses, and mechanisms of injury among pediatric dance‐related injuries in the United States. Methods A descriptive epidemiologic analysis of the National Electronic Injury Surveillance System from January 1, 2019 to December 31, 2023 identified emergency department presentations for primary dance ...
Katherine Koch, Philip M. Lee, Cameron Nishida, Sonya B. Levine, Kyle K. Obana, Jennifer M. Weiss, Jennifer King   +6 more
wiley   +1 more source

Community Health Worker Support for Hispanic and Latino Individuals Receiving Hemodialysis: The Navigate-Kidney Randomized Clinical Trial.

JAMA Intern Med
Cervantes L, Juarez-Colunga E, Powe NR, Flythe JE, Steiner JF, Cukor D, Hasnain-Wynia R, Furgeson S, Golestaneh L, Camacho C, McBeth L, Beaty BL, Shi J, Bacon E, Chonchol M.   +14 more
europepmc   +1 more source

Influence of Psychiatric Comorbidities on Postoperative Outcomes Following Pediatric Medial Patellofemoral Ligament Reconstruction

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To compare postoperative complications, rehabilitation outcomes, and health care utilization in children undergoing primary medial patellofemoral ligament reconstruction for patellofemoral instability with and without a pre‐existing mental illness. Methods The TriNetX U.S.
Haad A. Arif, Pearce Lane, Shamar T. Elliott, Amit Momaya, Kevin A. Williams   +4 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Environmental pollutant risk factors for worse COVID-19 related clinical outcomes in predominately hispanic and latino populations. [PDF]

Environ Res
Baumert BO, Wang H, Samy S, Park SK, Lam CN, Dunn K, Pinto-Pacheco B, Walker D, Landero J, Conti D, Chatzi L, Hu H, Goodrich JA.   +12 more
europepmc   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Technology-Based Interventions for Substance Use Treatment Among People Who Identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native: Scoping Review. [PDF]

J Med Internet Res
Moore SK, Boggis JS, Gauthier PR, Lambert-Harris CA, Hichborn EG, Bell KD, Saunders EC, Montgomery L, Murphy EI, Turner AM, Agosti N, McLeman BM, Marsch LA.   +12 more
europepmc   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)–exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort. Methods LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru,
Reem Farhat, Maria del Carmen Zamora‐Medina, Sang‐Cheol Bae, Megan R. W. Barber, Ann E. Clarke, Paul R. Fortin, Zahi Touma, Carl A. Laskin, Isabelle Malhamé, Giada Sebastiani, Christine Peschken, Manuel F. Ugarte‐Gil, Alexandra Legge, Sasha Bernatsky, Évelyne Vinet   +14 more
wiley   +1 more source